A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

← catalyst calendar

NCT07556159 · readout in 959 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Syneos Health.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

2,500estimated

Sites

Countries

Canada, Japan, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-01

actual

When the study began enrolling

Primary completion

2029-04-04

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-04-04

estimated

The whole study's end, after follow-up

First posted

2026-04-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Asthma

Interventions

Other: Procedure: Investigational Procedures
Other: Procedure: Investigational Procedures

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities

measured Part 1: At baseline

Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma

measured Part 1: At baseline

Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma

measured Part 1: At baseline

Part 1: Physician Global Assessment of Asthma Severity and Symptom Control

measured Part 1: At baseline

Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2

measured Part 2: At Weeks 52 and 104

Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2

measured Part 2: At Weeks 52 and 104

Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2

measured Part-2: At Weeks 52 and 104

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed